Multiple Myeloma

Educating Patients and Caregivers on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment

Findings from the phase 3 CARTITUDE-4 study support the supplemental biologics license application for ciltacabtagene autoleucel in the treatment of relapsed/refractory multiple myeloma.

Ajai Chari, MD;Kiah Purcell, AGPCNP-B;Annel Urena, RN, BSN;Robert Mancini, PharmD, BCOP

Treatment with Teclistamab Following Progression on CAR-T in R/R MM

The panel discusses how to educate patients and caregivers on infections risks when receiving an anti-BCMA bispecific antibody.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

FCRH5-Targeting and Other Emerging Bispecifics in R/R MM

The panel shares their experiences with the sequencing of BCMA-targeting therapies in MM, with particular focus on treatment of patients who progress on CAR T-cell therapy with teclistamab.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

MajesTEC-1: Data Updates of Anti-BCMA Bispecifics in MM

Jeremy Larsen, MD, discusses data from a phase 1/2 study of cevostamab and other emerging bispecifics being evaluated in patients with relapsed/refractory multiple myeloma.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Case 4: A 77-Year-Old with MM Treated with Bispecifics and Develops Neutropenia

Expert Shaji Kumar, MD, spearheads a review of data from MajesTEC-1 and use of teclistamab therapy in patients with relapsed/refractory multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP;Carlyn Tan, MD;Michael Scordo, MD;Anna Howard, RN

Overview of Treatment Options in Relapsed/Refractory Multiple Myeloma

An expert panel offers their initial impressions on the case of a 77-year-old with multiple myeloma treated with a BCMA bispecific antibody who develops neutropenia.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Managing Hypogammaglobulinemia Associated with Bispecifics in MM

Opening the panel’s discussion on multiple myeloma management, Rafael Fonseca, MD, reviews treatment options available to patients at early or late relapse.

Saad Z. Usmani, MD, MBA, FACP;Carlyn Tan, MD;Michael Scordo, MD;Anna Howard, RN

Bispecific Antibodies in Development for the Treatment of R/R MM

A panel of experts on multiple myeloma discuss the use of IVIG in the management of hypogammaglobulinemia in patients treated with bispecific antibodies.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

MonumenTAL-1: Evaluating the Anti- GPRC5D-Targetings Bispecific in R/R MM

Dr Jack Khouri highlights recent data updates on other BCMA-targeting bispecific antibodies that are in clinical development in multiple myeloma.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

Viral Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies

Dr Jeremy Larsen reviews data from the MonumenTAL-1 study investigating the CD3- and GPRC5D-targeting bispecific antibody talquetamab in relapsed/refractory multiple myeloma.

Ajai Chari, MD;Kiah Purcell, AGPCNP-B;Annel Urena, RN, BSN;Robert Mancini, PharmD, BCOP

Cilta-Cel Improves PFS Vs SOC Regimen in Lenalidomide-Refractory Myeloma

Robert Mancini, PharmD, explains the viral infections commonly seen in multiple myeloma patients treated with anti-BCMA bispecific antibodies.

$Ciltacabtagene autoleucel may become a new standard of care for patients with lenalidomide-refractory myeloma after first relapse, according to an expert from the Medical College of Wisconsin in Milwaukee.$

Chris Ryan

June 6th 2023

Ciltacabtagene autoleucel may become a new standard of care for patients with lenalidomide-refractory myeloma after first relapse, according to an expert from the Medical College of Wisconsin in Milwaukee.

Dosing and Sequencing Bispecifics and CAR T-Cell Therapies in R/R MM

Krina K. Patel, MD, MSc;Sairah Ahmed, MD;Melody R. Becnel, MD ;Tejo N. Musunuru, MD

June 5th 2023

Key opinion leaders share comprehensive insight on optimal dosing and sequencing strategies in patients with relapsed/refractory multiple myeloma.

RRMM: Access to Bispecifics and CAR T-Cell Therapy in Satellite Campuses

Krina K. Patel, MD, MSc;Sairah Ahmed, MD;Melody R. Becnel, MD ;Tejo N. Musunuru, MD

June 5th 2023

A brief conversation on the introduction and use of bispecifics and CAR T-cell therapies in satellite campuses for patients with relapsed/refractory multiple myeloma.

Novel CAR T Therapy Yields Safety, Responses in R/R Multiple Myeloma

Ryan Scott

Single-Agent Elranatamab Garners Robust, Durable Responses in Advanced Myeloma

GCF012F may show promising activity in relapsed and refractory multiple myeloma, according to an expert from Shanghai Chang Zheng Hospital.

$For the pooled analysis, investigators evaluated the efficacy and safety of bispecific antibody elranatamab in patients with relapsed/refractory multiple myeloma enrolled in 1 of the 4 MagnetisMM trials who received at least 1 proteasome inhibitor, 1 immunomodulatory drug, 1 anti-CD38 monoclonal antibody, and 1 BCMA-directed ADC and/or CAR T-cell therapy.$

Chris Ryan

Talquetamab/Daratumumab Garners Robust Response Rate in R/R Myeloma

For the pooled analysis, investigators evaluated the efficacy and safety of bispecific antibody elranatamab in patients with relapsed/refractory multiple myeloma enrolled in 1 of the 4 MagnetisMM trials who received at least 1 proteasome inhibitor, 1 immunomodulatory drug, 1 anti-CD38 monoclonal antibody, and 1 BCMA-directed ADC and/or CAR T-cell therapy.

$Numerous patients with heavily pretreated relapsed/refractory multiple myeloma responded following treatment with talquetamab and daratumumab.$

Caroline Seymour

Linvoseltamab Elicits Positive Efficacy in R/R Multiple Myeloma

Numerous patients with heavily pretreated relapsed/refractory multiple myeloma responded following treatment with talquetamab and daratumumab.

Silas Inman

Investigators Report Efficacy Trends With PHE885 in R/R Multiple Myeloma

Investigators report an increased objective response rate when linvoseltamab is given to patients with relapsed/refractory multiple myeloma.

Tony Berberabe, MPH

Teclistamab/Talquetamab Appears Tolerable in R/R Multiple Myeloma

A phase 1 trial continued to show positive responses when PHE885 was used in patients with relapsed/refractory multiple myeloma.

Silas Inman

June 3rd 2023

Results from the phase 1b RedirecTT-1 study show acceptable efficacy and safety when teclistamab plus talquetamab was given to patients with relapsed/refractory multiple myeloma.

$An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.$

‘Future Is Bright’ With Bispecifics for Relapsed/Refractory Myeloma

Bhagirathbhai Dholaria, MBBS

June 3rd 2023

An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.

Maintenance Therapy Regimens for Patients With Transplant-Eligible MM

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

June 2nd 2023

An expert panel discusses maintenance therapy for patients with MM and offers insights on how induction therapy impacts treatment options.

Determining Transplant Eligibility in Newly Diagnosed MM

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

June 2nd 2023

Experts on multiple myeloma (MM) discuss factors that determine transplant eligibility for patients who are newly diagnosed.

First-Line Treatment Options for Patients With Transplant-Ineligible NDMM

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

June 1st 2023

Ashley Rosko, MD, presents the case of a 79-year-old female with transplant-ineligible newly-diagnosed multiple myeloma.

Treatment Considerations for Patients with High-Risk NDMM

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

June 1st 2023

Barry Hammer, PA-C, defines high-risk multiple myeloma and explains the treatment adjustments needed for newly-diagnosed patients.

Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM Treatment

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)

Dr Cindy Varga discusses recent data on the FDA-approved agent teclistamab, a bispecific antibody for patients with relapsed/refractory multiple myeloma.

$Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)$

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM

Binod Dhakal, MD, MS, discusses the management of relapsed multiple myeloma and the various treatment options available.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Bacterial Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies

Maria-Victoria Mateos, MD, PhD, reviews how she manages the side effects of teclistamab, including cytokine release syndrome, in patients with relapsed/refractory multiple myeloma.

Ajai Chari, MD;Kiah Purcell, AGPCNP-B;Annel Urena, RN, BSN;Robert Mancini, PharmD, BCOP